Abstract
Acute FPIES reactions are characterized by different severity degrees (mild, moderate, and severe). The clinical management will involve different approaches depending on the severity of the reactions, with rehydration being the cornerstone of FPIES treatment. Oral rehydration at home is recommended in mild reactions, whereas intravenous fluid resuscitation is mandatory in severe forms characterized by protracted emesis, lethargy, pallor, diarrhea, hypotension, and metabolic acidosis. Indeed, acute FPIES can lead to hypovolemic shock, and consequently, the priority in management is restoration of hemodynamic stability. Recently, a possible role for parenteral ondansetron in controlling acute symptoms was suggested and recommended in severe reactions. In order to reduce a presumed cell-mediated inflammation, a single dose of intravenous methylprednisolone could be administered. Epinephrine autoinjectors are not recommended, because the hypotension occurred during a severe reaction is the result of fluid loss from the gastrointestinal symptoms. Epinephrine IV may be needed in case of hypovolemic shock not responsive to rehydration. The monitoring and measurement of vital signs is useful for providing real-time data and necessary to assess the clinical situation of the patient. If a progressive clinical worsening should be highlighted, the patient must be transferred to the intensive care unit for managing extreme lethargy, respiratory distress, persistent or severe hypotension even to a hypovolemic shock condition. A possible discharge can occur only when the clinical condition is completely restored, and the patient is able to tolerate oral fluids again. The history of severe FPIES reaction makes necessary to call immediately an ambulance or go to the nearest emergency department.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Powell GK. Enterocolitis in low-birth-weight infants associated with milk and soy protein intolerance. J Pediatr. 1976;88(5):840–4.
Nowak-Węgrzyn A, et al. International consensus guidelines for the diagnosis and management of food protein-induced enterocolitis syndrome: executive summary-Workgroup Report of the Adverse Reactions to Foods Committee, American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2017;139(4):1111–1126.e4.
Fiocchi A, Claps A, Dahdah L, Brindisi G, Dionisi-Vici C, Martelli A. Differential diagnosis of food protein-induced enterocolitis syndrome. Curr Opin Allergy Clin Immunol. 2014;14(3):246–54.
Monti G, et al. Food protein-induced enterocolitis syndrome by cow’s milk proteins passed through breast milk. J Allergy Clin Immunol. 2011;127(3):679–80.
Tan J, Campbell D, Mehr S. Food protein-induced enterocolitis syndrome in an exclusively breast-fed infant-an uncommon entity. J Allergy Clin Immunol. 2012;129(3):873.
Kimura M, Ito Y, Tokunaga F, Meguro T, Shimomura M, Morishita H, Seto S. Increased C-reactive protein and fever in Japanese infants with food protein-induced enterocolitis syndrome. Pediatr Int. 2016;58(9):826–30.
Kimura M, Ito Y, Shimomura M, Morishita H, Meguro T, Adachi Y, Seto S. Cytokine profile after oral food challenge in infants with food protein-induced enterocolitis syndrome. Allergol Int. 2017;66(3):452–7.
Pecora V, Prencipe G, Valluzzi R, Dahdah L, Insalaco A, Cianferoni A, De Benedetti F, Fiocchi A. Inflammatory events during food protein-induced enterocolitis syndrome reactions. Pediatr Allergy Immunol. 2017;28(5):464–70.
Dahdah L, Fiocchi A, Mazzina O, et al. FPIES: effects of educational intervention in an Italian children hospital. Allergy. 2014;60(Suppl 99):167.
Sicherer SH. Food protein-induced enterocolitis syndrome: case presentations and management lessons. J Allergy Clin Immunol. 2005;115(1):149–56.
Holbrook T, Keet CA, Frischmeyer-Guerreiro PA, Wood RA. Use of ondansetron for food protein-induced enterocolitis syndrome. J Allergy Clin Immunol. 2013;135(5):1219–20.
Miceli Sopo SM, Battista A, Greco M, Monaco S. Ondansetron for food protein-induced enterocolitis syndrome. Int Arch Allergy Immunol. 2014;164:137–9.
Cunningham RS. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Oncol Nurs Forum. 1997;24(7 Suppl):33–40.
Tomasik E, Ziółkowska E, Kołodziej M, Szajewska H. Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. Aliment Pharmacol Ther. 2016;44(5):438–46.
Bradley PB, Engel G, Feniuk W, et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 1986;25:563–76.
Doggrell SA, Hancox JC. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. Expert Opin Drug Saf. 2013;12(3):421–31.
Miceli Sopo S, Bersani G, Monaco S, Cerchiara G, Lee E, Campbell D, Mehr S. Ondansetron in acute food protein-induced enterocolitis syndrome, a retrospective case-control study. Allergy. 2017;72(4):545–51.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Fiocchi, A.G., Pecora, V. (2019). Management of Acute Food Protein-Induced Enterocolitis Syndrome (FPIES) Reactions. In: Brown-Whitehorn, T., Cianferoni, A. (eds) Food Protein Induced Enterocolitis (FPIES). Springer, Cham. https://doi.org/10.1007/978-3-030-21229-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-21229-2_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-21228-5
Online ISBN: 978-3-030-21229-2
eBook Packages: MedicineMedicine (R0)